tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

APLS Stock Latest News

Apellis Pharmaceuticals’ Phase 3 Study Update: Long-Term Efficacy of Pegcetacoplan
Company AnnouncementsApellis Pharmaceuticals’ Phase 3 Study Update: Long-Term Efficacy of Pegcetacoplan
3d ago
APLS
Apellis Pharmaceuticals’ Phase 3 Study on Pegcetacoplan: A Potential Game-Changer in AMD Treatment
PremiumCompany Announcements
Apellis Pharmaceuticals’ Phase 3 Study on Pegcetacoplan: A Potential Game-Changer in AMD Treatment
5d ago
APLS
Apellis, Sobi present data from open-label period of Phase 3 VALIANT study
PremiumThe Fly
Apellis, Sobi present data from open-label period of Phase 3 VALIANT study
23d ago
APLS
Apellis Pharmaceuticals Holds Annual Stockholders Meeting
PremiumCompany Announcements
Apellis Pharmaceuticals Holds Annual Stockholders Meeting
24d ago
8K
APLS
Apellis price target raised to $29 from $26 at Wells Fargo
PremiumThe Fly
Apellis price target raised to $29 from $26 at Wells Fargo
27d ago
APLS
Apellis price target raised to $29 from $26 at Wells Fargo
PremiumThe FlyApellis price target raised to $29 from $26 at Wells Fargo
27d ago
APLS
Cautious Hold on Apellis Pharmaceuticals Amid Uncertainties with Pegcetacoplan Launch and Financial Stability
Premium
Ratings
Cautious Hold on Apellis Pharmaceuticals Amid Uncertainties with Pegcetacoplan Launch and Financial Stability
27d ago
APLS
Apellis price target lowered to $41 from $49 at Citi
Premium
The Fly
Apellis price target lowered to $41 from $49 at Citi
1M ago
APLS
Apellis price target lowered to $20 from $30 at Mizuho
PremiumThe Fly
Apellis price target lowered to $20 from $30 at Mizuho
2M ago
APLS
Buy Recommendation for Apellis Pharmaceuticals Driven by Syfovre’s Market Potential and Strategic Expansion
PremiumRatings
Buy Recommendation for Apellis Pharmaceuticals Driven by Syfovre’s Market Potential and Strategic Expansion
2M ago
APLS
Qualcomm initiated, Lyft upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Qualcomm initiated, Lyft upgraded: Wall Street’s top analyst calls
2M ago
ROK
AFRM
Apellis downgraded to Neutral from Buy at BofA
PremiumThe Fly
Apellis downgraded to Neutral from Buy at BofA
2M ago
APLS
Apellis downgraded to Outperform from Strong Buy at Raymond James
PremiumThe FlyApellis downgraded to Outperform from Strong Buy at Raymond James
2M ago
APLS
Apellis price target lowered to $20 from $28 at Scotiabank
Premium
The Fly
Apellis price target lowered to $20 from $28 at Scotiabank
2M ago
APLS
Apellis price target lowered to $47 from $55 at Baird
Premium
The Fly
Apellis price target lowered to $47 from $55 at Baird
2M ago
APLS
Apellis price target lowered to $26 from $30 at Wells Fargo
PremiumThe Fly
Apellis price target lowered to $26 from $30 at Wells Fargo
2M ago
APLS
Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks
PremiumRatings
Optimistic Growth Potential for Apellis Pharmaceuticals Despite Temporary Setbacks
2M ago
APLS
Hold Rating on Apellis Pharmaceuticals Amid Revenue Uncertainty and Competitive Pressures
PremiumRatings
Hold Rating on Apellis Pharmaceuticals Amid Revenue Uncertainty and Competitive Pressures
2M ago
APLS
Apellis Pharmaceuticals Reports Q1 2025 Financial Results
PremiumCompany Announcements
Apellis Pharmaceuticals Reports Q1 2025 Financial Results
2M ago
APLS
Apellis Pharmaceuticals’ Earnings Call Highlights Achievements and Challenges
PremiumCompany AnnouncementsApellis Pharmaceuticals’ Earnings Call Highlights Achievements and Challenges
2M ago
APLS
Buy Rating Maintained for Apellis Pharmaceuticals Despite Short-Term Challenges
Premium
Ratings
Buy Rating Maintained for Apellis Pharmaceuticals Despite Short-Term Challenges
2M ago
APLS
Apellis Pharmaceuticals: Buy Rating Reaffirmed Amid Growth Potential and Market Leadership in GA
Premium
Ratings
Apellis Pharmaceuticals: Buy Rating Reaffirmed Amid Growth Potential and Market Leadership in GA
2M ago
APLS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >